FASTinov

FASTinov is a research and development-intensive startup specializing in rapid and reliable antimicrobial susceptibility tests for acute care settings. The company addresses the critical issue of antimicrobial resistance, which poses significant medical and economic challenges globally. Traditional methods for determining susceptibility profiles take at least 48 hours, forcing physicians to start broad-spectrum therapies empirically. FASTinov's innovative approach reduces this time to just 2 hours, offering a comprehensive solution that starts directly from positive blood cultures.

FASTinov's technology is based on the early detection of microbial cell lesions or metabolic changes using fluorochromes, which are substances that emit light when exposed to specific wavelengths. These changes are identified through flow cytometer analysis, making the process more automated and less dependent on the operator. The company provides an all-in-one kit that includes sample preparation materials, probes, antibiotics, reagents, and dedicated analytical software. This package ensures clear guidance for the best use of antibiotics based on established international recommendations from EUCAST and CLSI.

FASTinov serves healthcare providers in acute care settings, aiming to support clinical decisions with fast turnaround times. The business model revolves around selling its patented testing kits and software solutions to hospitals and medical laboratories. Revenue is generated through the sale of these kits and potentially through software licensing fees.

Keywords: antimicrobial susceptibility, rapid testing, acute care, patented technology, microbial detection, flow cytometry, healthcare, diagnostics, clinical decisions, EUCAST CLSI.